These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

476 related items for PubMed ID: 34904502

  • 1. Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma.
    Schmitt AM, Dumas L, Larkin J.
    Expert Rev Anticancer Ther; 2022 Jan; 22(1):17-25. PubMed ID: 34904502
    [Abstract] [Full Text] [Related]

  • 2. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial.
    Gutzmer R, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S, Pereira RP, Eigentler T, Rutkowski P, Demidov L, Manikhas GM, Yan Y, Huang KC, Uyei A, McNally V, McArthur GA, Ascierto PA.
    Lancet; 2020 Jun 13; 395(10240):1835-1844. PubMed ID: 32534646
    [Abstract] [Full Text] [Related]

  • 3. Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study.
    Dummer R, Queirolo P, Abajo Guijarro AM, Hu Y, Wang D, de Azevedo SJ, Robert C, Ascierto PA, Chiarion-Sileni V, Pronzato P, Spagnolo F, Mujika Eizmendi K, Liszkay G, de la Cruz Merino L, Tawbi H.
    Lancet Oncol; 2022 Sep 13; 23(9):1145-1155. PubMed ID: 35940183
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study.
    Ascierto PA, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S, Pereira RP, Eigentler T, Rutkowski P, Demidov L, Zhukova N, Schachter J, Yan Y, Caro I, Hertig C, Xue C, Kusters L, McArthur GA, Gutzmer R.
    Lancet Oncol; 2023 Jan 13; 24(1):33-44. PubMed ID: 36460017
    [Abstract] [Full Text] [Related]

  • 9. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
    Ascierto PA, McArthur GA, Dréno B, Atkinson V, Liszkay G, Di Giacomo AM, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Yan Y, Wongchenko M, Chang I, Hsu JJ, Koralek DO, Rooney I, Ribas A, Larkin J.
    Lancet Oncol; 2016 Sep 13; 17(9):1248-60. PubMed ID: 27480103
    [Abstract] [Full Text] [Related]

  • 10. Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFV600 mutation-positive melanoma.
    Robert C, Lewis KD, Gutzmer R, Stroyakovskiy D, Gogas H, Protsenko S, Pereira RP, Eigentler T, Rutkowski P, Demidov L, Caro I, Forbes H, Shah K, Yan Y, Li H, McArthur GA, Ascierto PA.
    Ann Oncol; 2022 May 13; 33(5):544-555. PubMed ID: 35131452
    [Abstract] [Full Text] [Related]

  • 11. Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma.
    Ribas A, Daud A, Pavlick AC, Gonzalez R, Lewis KD, Hamid O, Gajewski TF, Puzanov I, Wongchenko M, Rooney I, Hsu JJ, Yan Y, Park E, McArthur GA.
    Clin Cancer Res; 2020 Jan 01; 26(1):46-53. PubMed ID: 31732523
    [Abstract] [Full Text] [Related]

  • 12. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
    Hauschild A, Larkin J, Ribas A, Dréno B, Flaherty KT, Ascierto PA, Lewis KD, McKenna E, Zhu Q, Mun Y, McArthur GA.
    JAMA Oncol; 2018 Oct 01; 4(10):1382-1388. PubMed ID: 30073321
    [Abstract] [Full Text] [Related]

  • 13. The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma.
    Amaral T, Nouri N, Garbe C.
    Expert Rev Anticancer Ther; 2016 Jul 01; 16(7):705-15. PubMed ID: 27219630
    [Abstract] [Full Text] [Related]

  • 14. Cobimetinib Plus Vemurafenib: A Review in BRAF (V600) Mutation-Positive Unresectable or Metastatic Melanoma.
    Keating GM.
    Drugs; 2016 Apr 01; 76(5):605-15. PubMed ID: 26984388
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Cobimetinib and vemurafenib for the treatment of melanoma.
    Boespflug A, Thomas L.
    Expert Opin Pharmacother; 2016 Apr 01; 17(7):1005-11. PubMed ID: 26999478
    [Abstract] [Full Text] [Related]

  • 18. New primary melanoma in a patient under triple therapy with vemurafenib, cobimetinib, and atezolizumab for metastatic melanoma.
    Diamantopoulos PT, Lakiotaki E, Kyriakakis G, Gogas H.
    Melanoma Res; 2020 Apr 01; 30(2):206-208. PubMed ID: 31157737
    [Abstract] [Full Text] [Related]

  • 19. The role of triple therapy and therapy sequence in treatment of BRAF-mutant metastatic melanoma. Response to overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study.
    Dummer R, Welti M, Ramelyte E.
    J Transl Med; 2023 Aug 05; 21(1):529. PubMed ID: 37543586
    [Abstract] [Full Text] [Related]

  • 20. Combined BRAF, MEK, and heat-shock protein 90 inhibition in advanced BRAF V600-mutant melanoma.
    Eroglu Z, Chen YA, Smalley I, Li J, Markowitz JK, Brohl AS, Tetteh L, Taylor H, Sondak VK, Khushalani NI, Smalley KSM.
    Cancer; 2024 Jan 05; 130(2):232-243. PubMed ID: 37776537
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.